Form 4: Director Duncan Moore Adjusts Stake in ASP Isotopes

ASP Isotopes Director Duncan Moore acquired over 62,000 shares through stock awards before selling a portion to cover tax liabilities under a pre-arranged trading plan.

Summary

• Director Duncan Moore received two restricted stock awards totaling 62,017 shares between November and December 2025.
• The first award of 25,469 shares was granted for service on the QLE Structuring and Strategic Transactions Committee.
• The second award of 36,548 shares was an annual director equity grant for 2025.
• On April 16, 2026, Moore sold 11,642 shares at a weighted average price of $5.205 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on December 31, 2025, primarily to satisfy tax liabilities from vested awards.
• Following these transactions, Moore maintains a significant direct ownership of 1,044,928 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as neutral to slightly positive because the director's net ownership increased significantly over the period despite the small tax-related sale.

Positives

• The director maintains a very large position of over 1 million shares, showing long-term commitment.
• The sale represented only approximately 1.1% of the director's total holdings.
• The use of a Rule 10b5-1 plan provides transparency and reduces concerns regarding the timing of insider sales.

Negatives

• Insider selling, even for tax purposes, can occasionally create minor negative sentiment in the short term.

Risks

• Potential for further automated sales under the existing 10b5-1 plan which could create periodic downward pressure on the stock price.

Future Outlook

The reporting person continues to hold a substantial equity stake, suggesting long-term alignment with the company, though the 10b5-1 plan may trigger additional automated sales in the future to manage tax obligations or portfolio diversification.

Management Comments

• The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025.
• The sale includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award.

Industry Context

StockSavvy.ai notes that it is standard practice for directors of growth-stage companies to receive equity compensation and sell portions to cover tax obligations, especially when utilizing 10b5-1 plans to ensure regulatory compliance.

Comparison to Industry Standards

• Director equity grants are consistent with peers in the specialty chemicals and isotope sectors to align management with shareholder interests.
• The adoption of a 10b5-1 plan four months prior to the sale aligns with corporate governance best practices for insiders.

Corporate Governance

Related Party Transactions

• Issuance of equity to a director as compensation for services rendered to the company.

Stakeholder Impact

• Shareholders should note that high-level insider ownership remains intact, signaling confidence.
• Minimal dilution occurs from the issuance of new restricted shares relative to the total market capitalization.

Next Steps

• Monitor for further filings under the 10b5-1 plan to determine the total volume of planned sales.

Key Dates

Recommendation

This is a routine administrative filing showing a director managing their equity position. It does not signal a change in company fundamentals or strategic direction.

Keywords

ASP Isotopes, ASPI, Insider Trading, Form 4, Director Stock Award, Rule 10b5-1, Restricted Stock, Duncan Moore